Semax is a synthetic heptapeptide analog of adrenocorticotropic hormone fragment ACTH(4-7), developed in Russia and registered as a nootropic and neuroprotective drug. Research has demonstrated its ability to upregulate BDNF and NGF expression, protect neurons from ischemic damage, and enhance cognitive performance.
Molecular Structure and Stability
Native ACTH(4-7) (Met-Glu-His-Phe) has very poor metabolic stability. Semax extends this sequence with a Pro-Gly-Pro tripeptide to produce a compound with significantly improved resistance to enzymatic degradation, enabling intranasal administration with meaningful CNS exposure via olfactory pathways that bypass the blood-brain barrier.
Neurotrophic Factor Upregulation
Among Semax's most studied mechanisms is its ability to upregulate brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the brain. Both neurotrophins are critical for neuronal survival, synaptic plasticity, and cognitive function. BDNF upregulation is associated with enhanced learning and memory consolidation in animal models.
Neuroprotection and Stroke Research
Russian clinical studies have examined Semax in the context of ischemic stroke recovery, reporting improvements in neurological deficit scores and cognitive recovery markers. It is registered in Russia and Ukraine for stroke rehabilitation and cognitive impairment applications.
Cognitive Enhancement Research
Preclinical studies in rodent models have demonstrated improved performance on various cognitive tasks following Semax administration. Research has also explored its potential in ADHD-related attention and executive function domains.
Research Disclaimer: This article is for educational purposes only and does not constitute medical advice.